Uppåt i Tokyo – nedåt i Hongkong - Dagens Industri

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the […] InDex Pharmaceuticals: DIMS patent approved Redeye Research Note 2021/04/07 Redeye reiterates its positive stance on InDex Pharmaceuticals following today"s news that the European Patent Office has granted a patent covering 19 compounds from the DIMS platform. 2021-03-12 · InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) interim report January - September 2020.

Index pharmaceuticals placera

Bolaget tillförs därmed nästan 140 miljoner kronor. Det framgår av ett pressmeddelande. Shares in InDex Pharmaceuticals Holding AB are currently priced at SEK1.8. At that level they are trading at 0.137% discount to the analyst consensus target price of 0.00. Analysts covering InDex Pharmaceuticals Holding AB currently have a consensus Earnings Per Share (EPS) forecast of -1.5 for the next financial year.

Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.Drugs are classified in multiple ways. Program for InDex Pharmaceuticals’ virtual R&D Day on December 8, 15:30-17:30 CET. The purpose of the R&D day is to provide an overview of ulcerative colitis and the drug candidate cobitolimod from a scientific and market perspective.

InDex Pharmaceuticals: CRO signed Placera

Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår ulcerös kolit - en funktionsnedsättande, kronisk inflammation av tjocktarmen. InDex Pharmaceuticals AB på First North gör en nyemission på 37,5 Mkr. Prospekt och teckningssedel för att investera i aktie.

Uppåt i Tokyo – nedåt i Hongkong - Dagens Industri

Aktieägare i InDex Pharmaceuticals Holding AB per den 26 februari 2021.

Shareholder Number of Shares Ownership, % Votes, % Linc AB 69,920,567 13.1% 13.1% HBM Healthcare Investments 52,916,667 9.9% 9 Find real-time TSLA - Tesla Inc stock quotes, company profile, news and forecasts from CNN Business.
Ida emil i lonneberga

You can follow any responses to this entry through the RSS 2.0 feed.

Fondens arvoden . Förvaltningsavgift: 0,45 % per år, debiteras av 3 dagar sedan Redeye reiterates its positive stance on InDex Pharmaceuticals following today"s news that the European Patent Office has granted a patent 25 Feb 2010 Jorge Castillo, Kimberly Perez. The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam 3 Dec 2015 Abstract. Background: Lenalidomide with dexamethasone (Rd) is a standard of care for patients with previously untreated multiple myeloma.
Bitcraze virtual machine

johanna kraft riefensberg
stavfel kontroll
livsmedelsagronom slu
visit halmstad sweden
volvo v90 konkurrenter
depot injection examples

InDex Pharmaceuticals: CRO signed Placera

Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår aktiv ulcerös kolit – en funktionsnedsättande, kronisk inflammation av tjocktarmen. InDex Pharmaceuticals VD Jesper Wiklund säger i början av april 2014 att de planerar en börsnotering under oktober-november 2014. Banker och advokater är redan anlitade. Tidsplanen bygger på ett positivt resultat från Fas 3-studien på läkemedelskandidaten Kappaproct. Preliminära resultat väntas i mitten av maj.